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Abstract 
Maintenance of electric potential and synaptic transmission are energetically demanding tasks 
that neuronal metabolism must continually satisfy. Inability to fulfil these energy requirements 
leads to the development of neurodegenerative disorders, including Alzheimer’s disease. A 
prominent feature of Alzheimer’s disease is in fact neuronal glucose hypometabolism. Thus 
understanding the fine control of energetic metabolism might help to understand 
neurodegenerative disorders. Recent research has indicated that a novel class of signalling 
molecules, the inositol pyrophosphates, act as energy sensors. They are able to alter the balance 
between mitochondrial oxidative phosphorylation and glycolytic flux, ultimately affecting the 
cellular level of ATP. The neuronal inositol pyrophosphate synthesis relies on the activity of 
the neuron enriched inositol hexakisphosphate kinase 3 (IP6K3) enzyme. To verify an 
involvement of inositol pyrophosphate signalling in neurodegenerative disorders, we 
performed tagging single nucleotide polymorphism (SNP) analysis of the IP6K3 gene in 
patients with familial and sporadic late onset Alzheimer’s disease (LOAD). Two SNPs in the 
5′-flanking promoter region of the IP6K3 gene were found to be associated with sporadic 
LOAD. Characterising the functionality of the two polymorphisms by luciferase assay revealed 
that one of them (rs28607030) affects IP6K3 promoter activity, with the G allele showing an 
increased activity. As the same allele has a beneficial effect on disease risk, this may be related 
to upregulation of IP6K3 expression, with a consequent increase in inositol pyrophosphate 
synthesis. In conclusion, we provide the first evidence for a contribution of genetic variability 
in the IP6K3 gene to LOAD pathogenesis. 
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 1. Introduction 
 The binding of a specific hormone/ligand (a ‘first messenger’) to plasma membrane 
receptors results in the activation of intracellular signalling cascades, mediated by small 
molecules that are therefore called ‘second messengers’. The protein kinase A (PKA) activator 
cAMP and the calcium releasing factor Ins(1,4,5)P3 (hereafter IP3) represent the most classical 
examples of second messengers. While only two cyclic nucleotides, cAMP and cGMP, are 
recognized as cellular messengers, IP3 represents the forerunner of a large and growing family 
of signalling molecules: the inositol phosphates [1]. The lipid form, called inositides, comprises 
seven members that control membrane identity as well as signalling events (for review see [2]). 
The cytosolic, or water soluble, inositol phosphates encompass more than 40 identified 
members, able to regulate virtually every aspect of cellular physiology (for review see [3, 4]). 
 Though IP3 is historically and functionally the most important inositol phosphate, 
recently a subfamily of these signalling molecules, the inositol pyrophosphates, generated by 
sequential phosphorylation of IP3 (Figure 1A) are gaining in interest and functional importance 
(for review see [5-7]). The inositol pyrophosphates are inositol phosphate molecules containing 
one or more pyrophosphate (diphospho) moiety/ies. The best characterised member of this 
family is synthesised from the fully phosphorylated inositol phosphate IP6 (inositol 
hexakisphosphate, phytic acid or InsP6) and is called IP7 (diphosphoinositol pentakisphosphate 
or InsP7); it possesses a pyrophosphate moiety at position five (Figure 1B) [8]. The inositol 
hexakisphosphate kinase enzymes, IP6Ks, are responsible for IP7 synthesis [9] (Figure 1 A,B). 
Three IP6K genes are present in the human genome; IP6K1 (IHPK1) and IP6K2 (IHPK2, 
PiUS) are localised close to each other on the same cytogenetic band (3p21.31) on chromosome 
three, while IP6K3 (IHPK3) is localised on chromosome six (6p21.31). The PPIP5K enzymes 
can further phosphorylate IP7 to IP8, a species containing two pyrophosphate moieties (Figure 
1A). 
 The analysis of genetically engineered yeast, amoeba and mice has associated the 
absence of inositol pyrophosphates with a vast array of cell biological processes. Inositol 
pyrophosphates regulate telomere length [10, 11], vesicular trafficking [12], epigenetic 
mechanisms [13, 14], DNA recombination [15, 16], ROS signalling [17] and many other 
activities. The ability of inositol pyrophosphates to regulate the cellular level of ATP [18], the 
central molecule of intermediary metabolism, might explain the diversity of roles played by 
this class of molecules. These fundamental signalling roles support the notion that alteration of 
inositol pyrophosphate metabolism is manifested by the appearance of important human 
diseases such as cancer and diabetes. The generation of mouse knockout models has revealed 
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that ip6k1-/- mice have altered insulin signalling and are resistant to becoming obese [19], while 
ip6k2-/- mice are more susceptible to cancer [20]. Interestingly, the ip6k3-/- mouse model 
displays neurological defects of motor learning and coordination [21]. 
 New information on inositol pyrophosphates is coming from human genetic studies 
where polymorphisms of IP6Ks and/or their chromosomal locus have been associated with 
specific traits or diseases. The IP6K1 gene is disrupted at the 3p21.31 breakpoint in a family 
with type 2 diabetes mellitus [22]; interestingly, a Single Nucleotide Polymorphism (SNP) at 
the same genetic locus has associated IP6K1 with the pathogenesis of Crohn's disease [23]. 
The IP6K2 genetic locus seems associated with variants determining human height [24]. 
Remarkably, a SNP at the IP6K3 locus has also been associated with Crohn's disease in 
Koreans [25]. Furthermore, an IP6K3 SNP has been associated with serum phosphorus 
concentration [26]. This large scale genome-wide association study of serum phosphorus 
concentration revealed just seven gene polymorphisms associated with serum phosphorus 
concentration [26], thus the association of IP6K3 with blood phosphate level is of particular 
relevance. This genetic study is consistent with the demonstration that inositol pyrophosphates 
regulate phosphate metabolism in a lower eukaryote, the yeast Saccharomices cerevisiae [27]. 
While IP6K3 is biochemically the least characterised of the three mammalian IP6Ks, the 
characterized SNP represents the strongest genetic association published so far for any IP6Ks. 
Therefore, we decided to investigate the genetic contribution of this locus to common human 
complex diseases, by analysing the influence of IP6K3 gene variation on the susceptibility to 
late onset Alzheimer’s disease (LOAD), the most common form of neurodegenerative disorder 
in the elderly. It is characterized pathologically by neuronal loss and aggregation of two 
proteins, Aβ and tau, and clinically by a progressive loss of memory and impairment of 
cognitive ability.  
Our brain has a very high ATP requirement; while this organ represents about 2% of 
body mass it uses 20% of oxygen consumed by a resting human [28]. Neurons have high energy 
requirements to maintain synaptic transmission and electric potential [29]. Several converging 
lines of evidence have implicated alterations in global and regional brain energetics in the 
pathogenesis of neurodegenerative diseases [30]. In fact, the reduction of the cerebral 
metabolic rate for glucose in specific brain areas is one of the striking features of Alzheimer’s 
disease (AD) [31]. Moreover, a strong correlation between the spatial distribution of increased 
glycolysis, and Aβ plaques has been identified in the AD brain [32]. Therefore, since IP6K3 is 
expressed in neurons [21, 33], and since inositol pyrophosphates have been shown to regulate 
ATP concentration by altering the glycolytic/mitochondrial metabolic ratio [18], we 
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hypothesized that IP6K3 variants could impact on neuronal energy homeostasis and 
consequently on neurodegenerative LOAD processes. In order to verify this hypothesis, we 
performed tagging SNP analysis of the IP6K3 gene in patients with familial and sporadic 
LOAD, and age-matched healthy control subjects. Two SNPs in the 5′-flanking region were 
found to be associated with sporadic LOAD. In vitro experiments were undertaken to examine 
whether these SNPs have an effect on IP6K3 promoter activity. 
 
2. Material Methods 
2.1. Study population 
A total of 527 individuals from Southern Italy, including 280 patients with LOAD and 
247 unrelated healthy controls were considered in this study. These patients were recruited at 
the Regional Neurogenetics Centre (Calabria, Southern Italy). According to familiarity (at least 
one first-degree relative with AD), the cases were classified as affected by familial LOAD (N 
= 138 subjects, including in the study only one case per family) or sporadic LOAD (N = 142 
subjects).   
Clinical diagnosis for AD was performed through the criteria of the National Institute 
on Aging, and the Alzheimer’s Association workgroup [34]. All patients were fully 
characterised from a clinical point of view and a set of physical and biochemical parameters 
were measured. Cognitive status was investigated through Mini Mental State Examination 
(MMSE) [35]. MMSE scores were adjusted for age and educational level according to 
procedure reported in [36]. 
Control subjects were recruited in the same population as AD patients in the frame of 
different recruitment campaigns focused on the monitoring of the quality of aging in Calabria. 
All subjects were carefully assessed using a rigorous clinical history evaluation and a 
general/neurological examination, in order to exclude the presence of any neurological 
disorder. To avoid population stratification effects, only subjects with at least two generations 
of ancestors from the Calabria region were included in this study. 
 
2.2. Ethics statement 
The study protocol was approved by the local ethics committee and conducted in 
accordance with the provisions of the Helsinki Declaration; informed consent for genetic 
screening was obtained from the study participants or, where appropriate, a relative or legal 
representative. After written informed consent was signed, genomic DNA was extracted from 
peripheral blood, according to established protocols. 
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2.3. SNP Selection and Genotyping Assays 
A total of 17 SNPs within approximately 30 kb encompassing the entire IP6K3 gene 
and its 5’ and 3’ flanking regions were genotyped in all subjects included in the study. The 
SNPs were selected by a tagging approach using the Caucasian HapMap database 
(www.hapmap.org) based on pairwise r2 (≥0.8) among common SNPs with minor allele 
frequency (MAF ≥0.05). The rs9469578 polymorphism, associated with serum phosphorus 
concentration [26], was also included in the final tag SNP panel. Multiplex SNP genotyping 
was performed using iPlex Gold Genotyping Asssy and Sequenom MassArray (Sequenom, San 
Diego, CA, USA) technology, following the manufacturer’s instructions and as previously 
described [37]. SNP assays were designed using Sequenom’s MassARRAY Assay Design v3.0 
Software. Spectra were analyzed using MassARRAY Typer v3.4 Software (Sequenom). For 
quality control, 5% of the total number of samples was re-genotyped to assess the reliability of 
the genotype identification protocols. Concordance among duplicates was greater than 99.8% 
for all genotypes. For additional quality control, genotypes were excluded if Hardy-Weinberg 
equilibrium among controls p<0.05 or call rates <90%. Ultimately, two SNPs, rs559290 and 
rs6457740, were excluded from analysis because they deviated from HWE (P < 0.05), and one, 
r12203688, due to low genotyping success rates.  
 
2.4. Bioinformatic analyses 
To assess the potential function of the promoter phenotype-associated SNPs, in silico 
functional analysis was carried out using the freely available PROMO software 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) [38, 39]. The 
functionality of these SNPs (and those in strong linkage disequilibrium; r2 ≥ 0.9 ) was further 
explored using regulatory information from the ENCODE 
(https://genome.ucsc.edu/ENCODE/) [40] and  the Roadmap Epigenome Mapping projects 
(http://www.ppmroadmap.com/; Roadmap Epigenomics et al.,2015) as implemented in 
HaploReg (v4.1, www.broadinstitute.org/mammals/haploreg/) [41], and RegulomeDB 
(www.regulomedb.org/) [42]. 
 
2.5. Reporter constructs 
Two IP6K3 promoter regions of 777 nt containing the rs10947435 (G3392A (Pos. 
33718075) and rs28607030 (A2033G (Pos. 33716716)) polymorphisms were chemically 
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synthesized (MWG-Biotech AG) adding NheI and HindIII restriction sites at the 5’ and 3’ of 
the synthesized DNA. The SNP was localized 276 nt downstream of NheI and 500 nt upstream 
of HindIII site. The four plasmid synthesized were named pK31 ((A)rs28607030), pK32 
((G)rs28607030), pK33 ((A)rs10947435) and pK34 ((G)rs10947435). These constructs were 
digested by NheI and HindIII, and subcloned into the promoterless pGL3 Basic luciferase 
reporter vector (Promega) generating the following plasmids pGL3K31, pGL3K32, pGL3K33 
and pGL3K34. The final constructs and presence of the appropriate SNP was confirmed by 
DNA sequencing.  
 
2.6. Cell culture, transfection and luciferase assay 
The cell lines HEK293T and SH-SY5Y were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum, and maintained in 
a humidified atmosphere of 5% CO2 at 37°C.. Transfection of HEK293T cells was performed 
using Lipofectamine 2000 (Invitrogen) on 80% confluent cells in a 24 well plate, while SH-
SY5Y cells were transfected using TransFast (Promega) in a 12 well plate following the 
manufacturer’s protocol. The pGL3-IP6K3-SNP construct (pGL3K31 to 4), 100-500 ng, was 
cotransfected with 1-10 ng phRG-TK vector containing the Renilla luciferase (Promega) to 
correct for transfection efficiency. Twenty-four hours after transfection, cells were harvested 
or treated with Forskolin or the c-Myc inhibitor 10058-F4 (Sigma- Aldrich). Luciferase 
expression activities were assessed using the Stop & Glo kit (Promega) following 
manufacturer’s instructions. Firefly luciferase activity was normalized to Renilla luciferase 
activity. Differences in luciferase activity were compared using unpaired t-test. 
 
2.7. Statistical Analysis 
For each SNP, allele and genotype frequencies were estimated by gene counting from 
the observed genotypes. Departure from Hardy-Weinberg equilibrium was assessed for each 
SNP in controls using the χ2 test. Pairwise LD was estimated between SNPs based on r2 
statistics calculated in controls using Haploview software version 4.0 [43] (available from the 
Broad Institute at http://www.broad.mit.edu/mpg/haploview/). 
Logistic regression analysis was used to examine the differences in SNP genotype 
frequencies between cases and controls. The association analyses were based on the estimation 
of the odds ratios (ORs) and their 95% confidence intervals (CIs), using sex as covariate. 
Additive, dominant and recessive genetic models were evaluated for each SNP. Only the 
dominant model was considered where the minor allele homozygote count for either cases or 
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controls was <5%. Akaike’s Information Criterion (AIC) [44] was employed to determine the 
best-fitting model for each SNP. 
We assessed whether there was evidence of interaction between APOE-4 and SNPs 
that were found significant in the case–control analyses by including both the main effects for 
each variant and a product term (SNP x APOE-4) in the regression models.  
Statistical significance was considered to be p<0.05. As this study was exploratory, an arguably 
overly conservative statistical significance thresholding procedure (e.g., Bonferroni correction) 
was not employed.  The results were analyzed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). 
 
 
3. Results 
3.1. Genetic Analysis 
To investigate the contribution of IP6K3 genetic variability to the risk of late-onset 
Alzheimer disease (LOAD), we analyzed a cohort of 280 unrelated individuals with sporadic 
or familial LOAD, and a similarly aged cohort of 247 cognitively normal controls. 
Characteristics of the samples are given in Table 1. Seventeen SNPs were analysed in these 
populations, 14 of which passed the quality check. Figure 2 shows the physical location of 
these SNPs, and the linkage disequilibrium (LD) pattern in the control sample. Table 2 reports 
the results of the logistic regression analysis and presents the best model for association with 
LOAD risk. The ORs, adjusted for the gender, showed that two polymorphisms, rs28607030 
and rs10947435, both located in the 5′-flanking region of the gene, were associated with LOAD 
risk in the subgroup of patients with the sporadic form of the disease. For both SNPs the 
dominant model was the best-fitting model, but they were shown to have opposite effects on 
the disease risk. In fact, the carriers of at least one copy of the minor G allele of rs28607030 
were at a decreased risk of LOAD, with a statistically significant OR of 0.57 (OR=0.57; 95% 
CI 0.36–0.90; p= 0.011), whereas individuals carrying at least one copy of the minor A allele 
of rs10947435 were at higher LOAD risk, as compared to the group of carriers (OR 1.89; 95% 
CI 1.15–3.12; p= 0.010).  
We then tested for possible interactions between the IP6K3 SNPs and APOE status (ε4 
allele) but no significant interaction was observed, indicating that IP6K3 has an independent 
role in LOAD, irrespective of the presence of the APOE*4 allele. Also there was no significant 
association for age at onset, nor for the disease severity (measured by MMSE score).  
3.2 In silico functional consequences of rs28607030 and rs10947435 
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The identification of the two polymorphisms associated with LOAD risk in the 5′-
flanking region of the IP6K3 gene suggests that they might affect IP6K3 promoter 
functionality. To verify this hypothesis we first subjected the IP6K3 promoter region to an in 
silico search for putative transcription factor binding sites. We employed the freely available 
PROMO software and screened the promoter using a higher stringency with a maximum matrix 
dissimilarity rate of 5 [38, 39]. This analysis revealed that the polymorphism rs28607030 is 
located at the centre of a perfectly conserved, for the G allele, c-Myc binding site CACGTG, 
the underline indicating the SNP polymorphism [45]. Conversely, the polymorphism 
rs10347435 is located at the centre of a semi-conserved CREB binding site (cAMP response 
element, CRE) [46] with the underlined G allele TcACGTCA in the centre and the small letter 
indicating a mismatch compared to the consensus palindromic CRE sequence. 
Furthermore, since the observed associations might be due to different causal variants 
in LD with the studied ones, we annotated the two variants rs28607030 and rs10947435 and 
their proxies in high LD (r2 ≥0.9) for evidence of functionality using HaploReg v4.1 and 
RegulomeDB databases. LD patterns showed that the rs28607030 is not in LD with any other 
variants, while eleven SNPs, all in IP6K3, were identified that were proxies with the 
rs10947435. We found promising functional implications for these SNPs (i.e. promoter and 
enhancer histone marks, the presence of multiple DNase I hypersensitivity sites, and 
transcription factor binding sites; see Supplementary Material, Table S1 for details), indicating 
a regulatory potential. 
3.3. IP6K3 Promoter Activities 
To verify the existence of any functional effects of the SNPs located in putative 
transcription factor binding sites in the promoter region of the IP6K3 gene, four luciferase 
reporter constructs containing the SNP rs10947435 and rs28607030 were generated (Figure 
3A). Each construct was transfected into HEK293T cells and the relative promoter activities 
were determined by measuring luciferase expression (Figure 3B). This analysis revealed that 
while the SNP rs10947435 did not affect IP6K3 promoter fragment efficiency, the two alleles 
with SNP rs28607030 did show different IP6K3 promoter efficiencies. The construct 
pGL3K32 rs28607030, containing the G allele with a perfect match for c-Myc binding, was 
three times stronger that the pGL3K31 construct (the A allele). The difference in normalised 
luciferase activities between constructs possessing the SNP (A) or SNP (G) was statistically 
significant (Figure 3B). Similar studies were performed using human neuroblastoma SH-SY5Y 
cells, obtaining a substantially overlapping result (Figure 3C). Using SH-SY5Y we also did not 
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observe any effect of the SNP rs10947435 while the SNP rs28607030, containing the G allele, 
was almost twice as strong as the construct containing the A allele. 
The SNP rs10947435 is located in a semi-conserved cAMP response element (CRE), 
thus CREB binding may only occur after a strong stimulus. Therefore, we treated transfected 
HEK293T cells with forskolin, which increases the levels of cAMP by activating adenylyl 
cyclase. However, treating the cells with a wide range of forskolin concentration (1 to 50 M) 
and for 1 to 24 hours failed to reveal any effect of SNP rs10947435 on promoter activity (not 
shown).  
Since the polymorphism rs28607030 is located at the centre of a perfectly conserved c-
Myc binding site, to confirm its genuine nature we treated transfected HEK293T cells with the 
c-Myc inhibitor 10058-F4. This inhibitor, by destroying c-Myc-Max interaction, precludes 
transactivation of c-Myc target gene expression [47]. Treatment with 20 M of 10058-F4 for 
4 hours completely inhibited the transcriptional efficiency of SNP rs28607030 (Figure 3D), 
confirming that the A allele of this polymorphism abolishes a functional c-Myc binding site. 
 
4. Discussion 
Inositol is essential for correct neuronal development. In mouse, inositol prevents 
folate-resistant neural tube defects [48]. Inositol phosphate signalling is likely responsible for 
correct neuronal development, since neural tube defects are observable in the mouse knockout 
of the inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1 or PPK1) [49]. Inositol phosphate 
signalling is not only important during development but also for fine tuning adult brain 
function. In fact inositol polyphosphate multikinase (IPMK) loss of activity has been associated 
with the pathophysiology of Huntington’s disease [50]. Here, we define IP6K3 as an important 
player associated with LOAD. IP6K3 synthesizes the inositol pyrophosphate IP7, the best 
studied of a class of highly energetic signalling molecules acting as ‘metabolic messengers’ 
[51]. A recent review has in fact placed them ‘between’ signalling and metabolism [7]. The 
possible relevance of these molecules in the context of metabolic regulation is supported by 
several pieces of evidence. For example, inositol pyrophosphates regulate insulin secretion 
from pancreatic -cells [52] and insulin signalling [19]. 
Metabolism and AD are intimately linked. The brain is one of the most energy-
demanding organs in the body. It has evolved complex metabolic networks to maintain activity 
and energy metabolism, and any alteration in these may contribute to the neurodegenerative 
process. A growing body of evidence indeed supports the notion that AD represents a brain 
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metabolic disease. The co-existence of impaired glucose metabolism and insulin signaling in 
the brain has suggested that AD may represent a brain-specific form of diabetes, i.e., type 3 
diabetes or an insulin-resistant brain state [53, 54]. Multiple studies have also begun to outline 
an intricate connection between metabolic syndrome and AD. Individuals with metabolic 
syndrome-associated clinical features, such as diabetes, obesity, hypertension and dyslipidemia 
have a higher risk of developing AD [55-59].  
Thus, the regulation of inositol pyrophosphate synthesis, which have a central role in 
cellular metabolism and are crucial for the production and use of energy, may have a key role 
in the correlation between metabolism and AD. Here, we provide the first evidence for a 
contribution of genetic variability in the IP6K3 gene, which codes for one of the enzymes 
responsible for inositol pyrophosphate synthesis (Figure 1B) in neuronal cells [21, 33], to 
LOAD pathogenesis. We found that carriers of the minor allele of two IP6K3 5'-flanking region 
SNPs, rs28607030-G and rs10947435-A, were at decreased (OR=0.57; 95% CI 0.36–0.90; p= 
0.011) and increased (OR 1.89; 95% CI 1.15–3.12; p= 0.010) risk of LOAD, respectively. The 
two variants were found to affect susceptibility to sporadic LOAD while they appeared to not 
affect the chance of familial LOAD. This finding suggests that IP6K3 is likely to confer a low 
risk, which is covered by the major risk factors involved in familial LOAD. In addition, unlike 
other risk factors, it does not modulate the effect of major risk factor such as Apolipoprotein E 
(APOE) [60]. 
We analysed the role of the two SNPs associated with LOAD in modulating IP6K3 
promoter activity by using luciferase reporter assays. The SNP rs10947435 did not mediate 
gene activation. This specific polymorphism is located within a semi-conserved CRE element, 
which is the binding site for the transcription factor CREB. However, not all putative CREs 
are bound by CREB in resting conditions, as CREB does not constitutively interact with 
chromatin and its binding depends on stimulation in neurons [61, 62]. Therefore, it is possible 
that our inability to observe a transcriptional readout for SNP rs10947435 is due to the technical 
limitations of the luciferase reporter assays. However, we favour a different explanation: the 
rs10947435 SNP is likely a marker for another linked functional polymorphism which may 
account for the observed effect on the risk of disease. According to Hapmap data, this SNP is 
in strong linkage disequilibrium (LD; r2 ≥ 0.9) with 11 other SNPs within IP6K3. Moreover, 
in silico analysis by RegulomeDB revealed that three of the SNPs in LD with rs10947435 
(Table S1) have the highest level of evidence for a regulatory role; therefore, we cannot exclude 
the possibility that one of these markers may be the actual causal variant. Further studies are 
required to confirm these observations. 
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On the contrary, analysis of SNP rs28607030 pointed to a functional role for this 
polymorphism, showing greater transcriptional activity of the minor rs28607030 G allele that 
possesses an intact c-Myc binding site, with respect to the A allele. This SNP is not in LD with 
other polymorphisms; therefore, it is reasonable to speculate that rs28607030 could affect the 
activity of the IP6K3 promoter. Therefore the beneficial effect of the rs28607030 G allele on 
disease risk could be related to upregulation of expression of the gene and a consequent 
increase in IP7 production. 
 We are aware of the fact that our study has some weaknesses that should be addressed. 
First, a limitation of the study is the relatively small sample size, and therefore additional large 
studies are warranted to validate our findings. However, it is of note that all patients and 
controls were recruited in Calabria, a region from south Italy characterized, for historical and 
geographical reasons, by a homogeneous genetic background and therefore population 
stratification, which may substantially influence the results of analyses, is limited. A second 
limitation is the lack of proper correction for multiple testing. Since this study was exploratory, 
we did not control for type I errors, even though we conducted a relatively large number of 
statistical tests; a Bonferroni correction would have eliminated potentially important findings 
if applied. Despite these limitations, however, we believe that our study provides a starting 
point for shedding light on the potential function of inositol pyrophosphates in the nervous 
system, and could open a new avenue to potentially improve our understanding of LOAD 
pathogenesis. 
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Figure Legends 
Figure 1. Schematic of the inositol pyrophosphate biosynthetic pathway.  
The biochemical pathway of inositol pyrophosphate synthesis is illustrated in (A). The 
membrane phosphoinositide PI(4,5)P2 (PIP2) is hydrolysed by the action of Phospholipase C 
(PLC) to I(1,4,5)P3 (IP3). This is converted to IP4 by the IP3-3Kinase or the inositol 
polyphosphate multikinase (IPMK), which also converts IP4 to IP5. This is subsequently 
metabolised by the inositol pentakisphosphate 2-kinase (IP5-2K). The fully phosphorylated IP6 
is further acted on by inositol hexakisphosphate kinase (IP6K) to IP7 that can be further 
phosphorylated to IP8 by the PPIP5Ks. The chemical reaction catalysed by the mammalian 
IP6K3 enzyme, using ATP as phosphate donor and IP6, generating IP7 pyrophosphorylated at 
position 5 is depicted in (B). 
 
 
Figure 2: Location and linkage disequilibrium map of 14 SNPs in IP6K3.  
The relative physical position of each SNP is given in the upper diagram. Exons are represented 
by black boxes; non-coding exons by gray boxes; intronic and 5' and 3' regions are represented 
by solid lines. The dbSNP reference numbers are indicated below each SNP. The pairwise 
linkage disequilibrium coefficients r2 for the control participants were calculated using 
Haploview.  
 
 
Figure 3. Effect of rs28607030 and rs10947435 SNP on IP6K3 promoter activity. 
Schematic, to scale, of IP6K3 promoter region (A) with the sections containing the SNPs 
rs28607030 and rs10947435, used for luciferase assays, shown as boxes.The first transcribed 
exon (Exon 1) is positioned more than 11 Kb from the first protein coding exon containing the 
ATG translation start site. Luciferase reporter constructs were transfected into HEK293T cells 
(B) and SH-SY5Y cells (C). Luciferase activity was assayed 24 h post-transfection. The 
rs28607030 polymorphism affected promoter strength while the rs10947435 polymorphism 
did not. Transfected HEK293T cells were treated 24 h post-transfection for 4 h with the c-Myc 
inhibitor 100058-F4 at the indicated doses (D). 
The arbitrary units of firefly luciferase activity were normalized to renilla luciferase activity. 
Data are presented as average +/- standard deviation for experiments performed in triplicate. 
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p<0.01 (**); p<0.001 (***); not significant (ns). Representative results are shown; very similar 
results were obtained from three or two independent experiments for HEK293T and SH-SY5Y 
cells respectively .  
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Table 1. Baseline characteristics of the study participants. 
 LOAD Controls 
 (N=247)  Familial (N=138) Sporadic (N=142) 
Age (mean ± SD) 77.8 ± 4.9 77.8 ± 5.3 73.5 ± 8.8 
Males (%) 37.0 37.0 54.0 
Age onset (mean ± SD) 73.6 ± 5.39 73.9 ± 4.97 - 
MMSE* (mean ± SD) 14.35 ± 6.53 13.86 ± 7.11 23.84 ± 3.78  
APOE-ε4 carriers  (%) 45.26 37.90  8.33 
MMSE scores were adjusted for educational level and age at inclusion in the present study 
according to procedure reported in [36]. 
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Table 2. Logistic regression analysis for the association between IP6K3 genotypes and the risk of LOAD 
  Frequency Familial vs Controls Sporadic vs controls 
SNP 
 
Minor  
allele 
Controls  
(N=247) 
Familial  
(N=138) 
Sporadic  
(N=142) 
OR 95% CI PModel OR 95% CI PModel 
rs4713668 T 
45% 41% 48% 0.77 0.49-1.19 0.24D 1.27  0.79-2.06 0.32D 
rs34252064 A 5% 5% 4% 1.31  0.60-2.86 0.50
D 1.17*  0.50-2.75 0.72D 
rs12661400 T 22% 17% 16% 0.83*  0.53-1.32 0.43
D 0.66*  0.40-1.07 0.09D 
rs622917 T 
50% 48% 47% 0.81  0.50-1.32 0.40D 0.86  0.50-1.46 0.57R 
rs623813 T 13% 16% 15% 2.23 0.72-6.88 0.16
R 1.30  0.78-2.16 0.32D 
rs545787 A 31% 29% 29% 0.74 0.32-1.70 0.47
R 0.89  0.56-1.41 0.61D 
rs9469578 T 9% 7% 9% 0.67* 0.35-1.27 0.22
D 0.79*  0.42-1.51 0.47D 
rs791904 A 15% 16% 16% 1.15  0.71-1.88 0.57
D 1.17  0.70-1.94 0.56D 
rs16869463 T 9% 8% 8% 0.78*  0.43-1.43 0.42
D 0.77  0.40-1.47 0.42D 
rs78748610 C 8% 7% 6% 0.88* 0.47-1.65 0.69
D 0.76* 0.38-1.49 0.41D 
rs28607030 G 37% 35% 29% 0.82  0.53-1.27 0.38
D 0.57  0.36-0.90 0.011D 
rs9469583 T 
50% 50% 44% 0.87  0.53-1.44 0.60D 0.65  0.36-1.16 0.14R 
rs10947435 A 39% 43% 47% 1.28  0.81-2.03 0.29
D 1.90  1.15-3.14 0.010D 
rs4713675 T 
45% 47% 52% 1.41  0.83-2.40 0.21 R 1.45 0.85-2.48  0.17 D 
 
OR, odds ratio; CI, 95% confidence interval. OR adjusted for sex. Significant results in bold. 
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PModel is the p-value of the best-fit genetic model. The choice of each genetic model was based on AIC value. D is dominant model (LOAD risk in 
heterozygotes or minor allele homozygotes relative to common allele homozygotes) and R is recessive model (LOAD risk in minor allele 
homozygotes relative to common allele homozygotes or heterozygotes). 
* For these SNPs only the dominant model was considered since the rare homozygous genotype was less than 3%.
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